abbv-8e12
mAbexperimental
Clinical trial activity
7 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2015 (NCT02494024)
Timeline
Indications
Mechanism of action
- Microtubule-associated protein tauINHIBITOR
MAPT inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- abbv-8e12
- c2n-8e12
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03712787 | Phase 2 | Mar 22, 2019 | AbbVie |
| NCT03413319 | Phase 1 | Apr 17, 2018 | AbbVie |
| NCT03391765 | Phase 2 | Jan 24, 2018 | AbbVie |
| NCT02985879 | Phase 2 | Dec 16, 2016 | AbbVie |
| NCT02880956 | Phase 2 | Oct 17, 2016 | AbbVie |
| NCT02494024 | Phase 1 | Jul 1, 2015 | C2N Diagnostics, University of California, San Francisco |
| NCT03744546 | N/A | — | AbbVie |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 6 | 6 | 3 | 2016 |
| C2N Diagnostics | For profit | 1 | 1 | 1 | 2015 |
| University of California, San Francisco | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1